{"title":"Lymphoma","description":null,"products":[{"product_id":"phoixaz-4-ixazomib","title":"TAZEDX (Tazemetostat)","description":"\u003ch2\u003eAbout Tazemetostat\u003c\/h2\u003e\u003cp\u003eTazemetostat is a selective inhibitor of EZH2, administered orally.It is approved treatment for Follicular lymphoma and epithelioid sarcoma.\u003c\/p\u003e\u003ch2\u003eEpithelial Sarcoma\u003c\/h2\u003e\u003cp\u003eIndicated for metastatic or locally advanced epithelioid sarcoma not eligible for complete resection\u003c\/p\u003e\u003cp\u003e800 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003eFollicular Lymphoma\u003c\/h2\u003e\u003cp\u003eIndicated for relapsed or refractory (R\/R) follicular lymphoma (FL) in patients whose tumors are positive for EZH2 mutation and who have received at least 2 prior systemic therapies\u003c\/p\u003e\u003cp\u003eAlso, indicated for R\/R FL in adults who have no satisfactory alternative treatment options\u003c\/p\u003e\u003cp\u003e800 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003eDose reduction schedule\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eFirst reduction: 600 mg PO BID\u003c\/li\u003e\n\u003cli\u003eSecond reduction: 400 mg PO BID\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if unable to tolerate 400 mg BID\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797945839659,"sku":"RL28202408161765","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-08-2175.jpg?v=1787022063"},{"product_id":"sugemalimab-cejemly","title":"Cejemly (Sugemalimab)","description":"\u003ch2\u003eAbout Cejemly® (Sugemalimab)\u003c\/h2\u003e\u003cp\u003eThe anti-PD-L1 monoclonal antibody sugemalimab was discovered by CStone using the OmniRat\u003csup\u003e®\u003c\/sup\u003e transgenic animal platform, which allows creation of fully human antibodies in one step. Sugemalimab is a fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) monoclonal antibody, which may reduce the risk of immunogenicity and toxicity for patients, a unique advantage over similar drugs.\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Approval\"\u003eApproval\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eThe NMPA of China has approved sugemalimab for four indications:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eIn combination with chemotherapy for first-line treatment of patients with metastatic squamous and non-squamous NSCLC.\u003c\/li\u003e\n\u003cli\u003eFor the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy.\u003c\/li\u003e\n\u003cli\u003eFor the treatment of patients with relapsed or refractory extranodal NK\/T-cell lymphoma.\u003c\/li\u003e\n\u003cli\u003eIn combination with fluorouracil and platinum-based chemotherapy for first-line treatment of patients with unresectable locally advanced, recurrent or metastatic ESCC.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cspan class=\"LEwnzc Sqrs4e\"\u003eJuly 26, 2024 — \u003c\/span\u003eCStone Announces European Commission (EC) Approval of \u003cem\u003eCejemly\u003c\/em\u003e® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSugemalimab sold as brand name 择捷美® in china.\u003c\/li\u003e\n\u003cli\u003eSugemalimab sold as brand name Cejemly® in European Union.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eReference: 《\u003ca href=\"https:\/\/www.prnewswire.com\/news-releases\/cstone-announces-european-commission-approval-of-sugemalimab-cejemly-as-first-line-treatment-for-non-small-cell-lung-cancer-302207524.html\"\u003eCStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer\u003c\/a\u003e 》\u003c\/p\u003e","brand":"CStone Pharmaceuticals","offers":[{"title":"Default Title","offer_id":44797945970731,"sku":"RL29","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-07-262.png?v=1787022066"},{"product_id":"ibrutily-emlutini-2","title":"ILUDX (Ibrutinib)","description":"Ibrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.\r\n\u003ch3\u003e\u003cspan id=\"Chronic_Lymphocytic_LeukemiaSmall_Lymphocytic_Lymphoma\"\u003eChronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma\u003c\/span\u003e\u003c\/h3\u003e\r\nAlso indicated for CLL\/SLL in patients with 17p deletion\r\n\r\nMonotherapy or in combination with rituximab or obinutuzumab, or with bendamustine and rituximab (BR) combination: 420 mg PO qDay\r\n\r\nContinue until unacceptable toxicity or disease progression\r\n\u003ch3\u003e\u003cspan id=\"Mantle_Cell_Lymphoma\"\u003eMantle Cell Lymphoma\u003c\/span\u003e\u003c\/h3\u003e\r\nIndication was voluntary withdrawn in the U.S. by manufacturer on April 10, 2023\r\n\r\nThe decision was made to remove the indication after overall survival (OS) was similar when comparing ibrutinib or placebo in combination with bendamustine and rituximab for mantle cell lymphoma in the phase 3 SHINE trial\r\n\r\nFailure to meet this requirement led to the decision to remove the indication after consulting the FDA\r\n\u003ch3\u003e\u003cspan id=\"Waldenstrom_Macroglobulinemia\"\u003eWaldenström Macroglobulinemia\u003c\/span\u003e\u003c\/h3\u003e\r\nIndicated as monotherapy or in combination with rituximab\r\n\r\n420 mg PO qDay\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003e\u003cspan id=\"Marginal_Zone_Lymphoma\"\u003eMarginal Zone Lymphoma\u003c\/span\u003e\u003c\/h3\u003e\r\nIndication was voluntary withdrawn in the U.S. by manufacturer on April 10, 2023\r\n\r\nThe decision was made to remove the indication after the phase 3 SELENE trial failed to reach its primary endpoint of progression free survival (PFS) when comparing ibrutinib to placebo in combination with bendamustine and rituximab or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated MZL\r\n\r\nFailure to meet this requirement led to the decision to remove the indication after consulting the FDA\r\n\u003ch3\u003e\u003cspan id=\"Chronic_Graft_vs_Host_Disease\"\u003eChronic Graft vs Host Disease\u003c\/span\u003e\u003c\/h3\u003e\r\nIndicated for chronic graft versus host disease (cGVHD) in adults who failed \u0026gt;1 lines of systemic therapy\r\n\r\n420 mg PO qDay\r\n\r\nContinue until cGVHD progression, recurrence of an underlying malignancy, or unacceptable toxicity\r\n\r\nIf therapy is no longer required, consider discontinuing therapy based on medical assessment of individual patient\r\n\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003ch4\u003e\u003cspan id=\"Grade_2_cardiac_failure\"\u003eGrade 2 cardiac failure\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eEvaluate benefit-risk before resuming treatment\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"MCL_and_MZL\"\u003eMCL and MZL\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Restart at 420 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Restart at 280 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: Discontinue therapy\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"CLLSLL_WM_and_cGVHD\"\u003eCLL\/SLL, WM, and cGVHD\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Restart at 280 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Restart at 140 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: Discontinue therapy\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Grade_3_cardiac_arrhythmias\"\u003eGrade 3 cardiac arrhythmias\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"MCL_and_MZL1\"\u003eMCL and MZL\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Restart at 420 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Discontinue therapy\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"CLLSLL_WM_and_cGVHD1\"\u003eCLL\/SLL, WM, and cGVHD\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Restart at 280 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Discontinue therapy\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Grade_3_cardiac_failure_or_Grade_4_cardiac_arrhythmias\"\u003eGrade ≥3 cardiac failure or Grade 4 cardiac arrhythmias\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Discontinue therapy\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Nonhematological_and_hematologic_toxicities\"\u003eNonhematological and hematologic toxicities\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eOther Grade 3 or 4 nonhematological toxicities\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 3 or 4 neutropenia with infection or fever\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4 hematological toxicities\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"MCL_and_MZL2\"\u003eMCL and MZL\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Restart at 420 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Restart at 280 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: Discontinue therapy\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"CLLSLL_WM_and_cGVHD2\"\u003eCLL\/SLL, WM, and cGVHD\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Restart at 280 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Restart at 140 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: Discontinue therapy\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Coadministration_with_CYP3A_inhibitors\"\u003eCoadministration with CYP3A inhibitors\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eModerate CYP3A4 inhibitor: Reduce ibrutinib to 420 mg qDay; modify dose as recommended\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Reduce_ibrutinib_dose_to_280_mg_qDay_when_coadministered_with_the_following\"\u003eReduce ibrutinib dose to 280 mg qDay when coadministered with the following\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eVoriconazole 200 mg BID\u003c\/li\u003e\r\n \t\u003cli\u003ePosaconazole suspension 100 mg qDay, 100 mg BID, or 200 mg BID\u003c\/li\u003e\r\n \t\u003cli\u003eModify dose as recommended\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Reduce_ibrutinib_dose_to_140_mg_qDay_when_coadministered_with_the_following\"\u003eReduce ibrutinib dose to 140 mg qDay when coadministered with the following\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003ePosaconazole suspension 200 mg TID or 400 mg BID\u003c\/li\u003e\r\n \t\u003cli\u003ePosaconazole IV injection 300 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003ePosaconazole delayed-release tablets 300 mg qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Avoid_coadministration\"\u003eAvoid coadministration\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eOther strong CYP3A inhibitors (boceprevir, clarithromycin, cobicistat conivaptan, danoprevir and ritonavir, diltiazem, elvitegravir and ritonavir, idelalisib, indinavir and ritonavir, itraconazole, ketoconazole, lopinavir and ritonavir, nefazodone, nelfinavir, paritaprevir and ritonavir and [ombitasvir and\/or dasabuvir], ritonavir, saquinavir and ritonavir, tipranavir and ritonavir, and troleandomycin)\u003c\/li\u003e\r\n \t\u003cli\u003eIf these inhibitors will be used short term (eg, anti-infectives for \u0026lt;7 days), interrupt ibrutinib\u003c\/li\u003e\r\n \t\u003cli\u003eAfter discontinuation of a CYP3A inhibitor, resume previous dose of ibrutinib\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eModify dose based on following ULN unless of non-hepatic origin or due to Gilbert’s syndrome\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Total_bilirubin_TB_level_15_to_3x_ULN\"\u003eTotal bilirubin (TB) level \u0026gt;1.5 to 3x ULN\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e≥1 to \u0026lt;12 years: Reduce to 80 mg\/m\u003csup\u003e2\u003c\/sup\u003e PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003e≥12 years: Reduce to 140 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eTB \u0026gt;3x ULN: Avoid use\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\r\nMild-to-moderate (eCrCl ≥25 mL\/min): No dosage adjustment necessary\r\n\r\nSevere (eCrCl \u0026lt;25 mL\/min) or patients on dialysis: Not studied","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797946462251,"sku":"RL1420230901310","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-08-2823.jpg?v=1787022074"},{"product_id":"cerini-certinib-150mg-2","title":"Alynni (Alectinib)","description":"Alectinib is a type of cancer growth blocker called a tyrosine kinase inhibitor. It works by blocking certain chemical messengers that tell cells to grow. This stops or slows down the cancer.\r\n\u003ch3\u003eApproval in Japan\u003c\/h3\u003e\r\n\u003cp class=\"heading-title\"\u003eAlectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma .\u003c\/p\u003e\r\n\r\n\u003ch3\u003eNon-small Cell Lung Cancer\u003c\/h3\u003e\r\nIndicated for anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test\r\n\r\n600 mg PO BID until disease progression or unacceptable toxicity\r\n\r\nSee Administration\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\n\u003ch4\u003eDose reduction schedule\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eStarting dose: 600 mg PO BID\u003c\/li\u003e\r\n \t\u003cli\u003eFirst dose reduction: 450 mg PO BID\u003c\/li\u003e\r\n \t\u003cli\u003eSecond dose reduction: 300 mg PO BID\u003c\/li\u003e\r\n \t\u003cli\u003eDiscontinue if patients are unable to tolerate 300 mg PO BID\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947379755,"sku":"RL1420230901745","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1655105951-634aa7e02ad1412.jpg?v=1787022092"},{"product_id":"acaluni-acalabrutinib-2","title":"Acaluni (Acalabrutinib)","description":"Acalabrutinib is used to treat people with mantle cell lymphoma (MCL; a fast-growing cancer that begins in the cells of the immune system) who have already been treated with at least one other chemotherapy medication. It is also used alone or with obinutuzumab (Gazyva) to treat chronic lymphocytic leukemia (CLL; a type of cancer that begins in the white blood cells) and small lymphocytic lymphoma (SLL: a type of cancer that begins in the white blood cells). Acalabrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.\r\n\r\nADULT\r\n\u003ch3\u003eMantle Cell Lymphoma\u003c\/h3\u003e\r\nIndicated for mantle cell lymphoma (MCL) in patients who have received ≥1 prior therapy\r\n\r\n100 mg PO q12hr\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003eChronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\u003c\/h3\u003e\r\nIndicated for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)\r\n\u003ch4\u003eMonotherapy\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e100 mg PO q12hr\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eCombination with obinutuzumab\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIndicated for patients with previously untreated CLL or SLL\u003c\/li\u003e\r\n \t\u003cli\u003eStart acalabrutinib at Cycle 1 (each cycle is 28 days)\u003c\/li\u003e\r\n \t\u003cli\u003eStart obinutuzumab at Cycle 2 for a total of 6 cycles\u003c\/li\u003e\r\n \t\u003cli\u003eRefer to obinutuzumab for infusion rates\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eCycle 1\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDays 1-28: Acalabrutinib 100 mg PO q12hr\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eCycle 2\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDays 1-28: Acalabrutinib 100 mg PO q12hr\u003c\/li\u003e\r\n \t\u003cli\u003eDay 1: Obinutuzumab 100 mg IV infusion\u003c\/li\u003e\r\n \t\u003cli\u003eDay 2: Obinutuzumab 900 mg IV infusion\u003c\/li\u003e\r\n \t\u003cli\u003eDays 8 and 15: Obinutuzumab 1000 mg IV infusion\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eCycles 3-7\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDay 1-28: Acalabrutinib 100 mg PO q12hr\u003c\/li\u003e\r\n \t\u003cli\u003eDay 1: Obinutuzumab 1000 mg IV infusion\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eCycle 8 and subsequent cycles\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDay 1-28: Acalabrutinib 100 mg PO q12hr\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947805739,"sku":"RL14202309011310","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-04-2050.png?v=1787022102"},{"product_id":"emlutini-ibrutinib-2","title":"Emlutini (Ibrutinib)","description":"Ibrutinib, sold under the brand name Emlutini, Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton's tyrosine kinase (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers. Ibrutinib is therefore used to treat such cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia.\r\n\r\nIt is on the World Health Organization's List of Essential Medicines.\r\n\u003ch2\u003eMedical uses\u003c\/h2\u003e\r\nIbrutinib is used to treat chronic lymphocytic leukemia (CLL), Waldenström's macroglobulinemia, and as a second-line treatment for mantle cell lymphoma, marginal zone lymphoma, and chronic graft vs host disease. BTK inhibition by ibrutinib impairs the BCR signalling pathway, which is a key dependency of malignant B cells, but it has been shown that BTK inhibition also interferes with CD40 signalling, B cell adhesion and migration.\r\n\r\nIn the United States ibrutinib is indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy, adults with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) with or without 17p deletion, adults with Waldenström's macroglobulinemia (WM), adults with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy, adults with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.\r\n\r\nIt is a first line treatment in those with CLL who require treatment and are newly diagnosed.[11] It may also be used in CLL that relapses.\r\n\r\nWhy is this medication prescribed?\r\n\u003ch2\u003eIbrutinib is used\u003c\/h2\u003e\r\nto treat people with mantle cell lymphoma (MCL; a fast-growing cancer that begins in the cells of the immune system) who have already been treated with at least one other chemotherapy medication,\r\nto treat people with chronic lymphocytic leukemia (CLL; a type of cancer that begins in the white blood cells) and small lymphocytic lymphoma (SLL; a type of cancer that begins mostly in the lymph nodes),\r\nto treat people with Waldenstrom's macroglobulinemia (WM; a slow-growing cancer that begins in certain white blood cells in your bone marrow),\r\nto treat people with marginal zone lymphoma (MZL; a slow growing cancer that begins in a type of white blood cells that normally fights infection) who have already been treated with a certain type of chemotherapy medication,\r\nand to treat people with chronic graft vs host disease (cGVHD; a complication of hematopoietic stem-cell transplant [HSCT; a procedure that replaces diseased bone marrow with healthy bone marrow] that may start a while after the transplant and last for a long time) after being treated unsuccessfully with 1 or more medications.\r\nIbrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.\r\n\u003ch2\u003eHow should this medicine be used?\u003c\/h2\u003e\r\nIbrutinib comes as a capsule and a tablet to take by mouth. It is usually taken once daily. Take ibrutinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take ibrutinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\r\n\r\nSwallow the capsules whole with a glass of water; do not open, break, or chew them. Swallow the tablets whole with a glass of water; do not cut, crush or chew them.\r\n\r\nIf you are receiving obinutuzumab (Gazyva) injection or rituximab (Rituxan) injection, your doctor may tell you to take your dose of imbrutinib before you receive your injection.\r\n\r\nYour doctor may decrease your dose, or interrupt or discontinue your treament. This depends on how well the medication works for you and the side effects you experience. Talk to your doctor about how you are feeling during your treatment. Continue to take ibrutinib even if you feel well. Do not stop taking ibrutinib without talking to your doctor.\r\n\r\nAsk your pharmacist or doctor for a copy of the manufacturer's information for the patient.\r\n\r\n\u003cstrong\u003eOther uses for this medicine\u003c\/strong\u003e\r\nThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\r\n\u003ch2\u003eWhat side effects can this medication cause?\u003c\/h2\u003e\r\nIbrutinib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:\r\ndiarrhea\r\nnausea\r\nconstipation\r\nvomiting\r\nstomach pain\r\nheartburn or indigestion\r\ndecreased appetite\r\nexcessive tiredness or weakness\r\nmuscle, bone, and joint pain\r\nmuscle spasms\r\nswelling of the hands, feet, ankles, or lower legs\r\nrash\r\nitching\r\nsores in the mouth and throat\r\nanxiety\r\ndifficulty falling asleep or staying asleep\r\ncough, runny or stuffed nose\r\nblurred vision\r\ndry or watery eyes\r\npink eye.","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797948133419,"sku":"RL1420230901356","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-04-2083.png?v=1787022108"},{"product_id":"generic-crizotinib","title":"Kayzoni (Crizotinib)","description":"\u003cp\u003eCrizotinib is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1.\u003c\/p\u003e\u003ch3\u003eNon-Small Cell Lung Cancer\u003c\/h3\u003e\u003cp\u003eIndicated for metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are anaplastic lymphoma kinase (ALK)- or ROS1-positive\u003c\/p\u003e\u003cp\u003e250 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eInflammatory Myofibroblastic tumors\u003c\/h3\u003e\u003cp\u003eIndicated for unresectable, recurrent, or refractory inflammatory myofibroblastic tumors (IMT) in adults who are ALK-positive\u003c\/p\u003e\u003cp\u003e250 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 200 mg PO BID\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 250 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 250 mg PO qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797948756011,"sku":"RL1020230315560","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-04-1046.jpg?v=1787022123"},{"product_id":"generic-selinexor-sailidx","title":"SALLYDX (Selinexor)","description":"Selinexor is used along with dexamethasone to treat multiple myeloma (a type of cancer of the bone marrow) that has returned or that did not respond to at least 4 other treatments.\r\n\u003ch3\u003eMultiple Myeloma\u003c\/h3\u003e\r\n\u003ch4\u003eIn combination with bortezomib and dexamethasone (SVd)\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIndicated, in combination with bortezomib and dexamethasone, for multiple myeloma (MM) have received ≥1 prior therapy\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e35-day cycle\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eSelinexor 100 mg PO qWeek on Day 1; continue until disease progression or unacceptable toxicity\u003c\/li\u003e\r\n \t\u003cli\u003eBortezomib 1.3 mg\/m\u003csup\u003e2\u003c\/sup\u003e SC qWeek on Day of each week x 4 weeks followed by 1 week off\u003c\/li\u003e\r\n \t\u003cli\u003eDexamethasone 20 mg PO twice weekly on Days 1 and 2 of each week\u003c\/li\u003e\r\n \t\u003cli\u003eRefer to prescribing information of bortezomib and dexamethasone for additional dosing information\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eIn combination with dexamethasone (Sd)\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIndicated in combination with dexamethasone for adults with relapsed or refractory multiple myeloma (RRMM) who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody\u003c\/li\u003e\r\n \t\u003cli\u003eSelinexor 80 mg PO plus dexamethasone 20 mg PO on Days 1 and 3 of each week\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\r\n \t\u003cli\u003eRefer to prescribing information of dexamethasone for additional dosing information\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eDiffuse Large B-Cell Lymphoma\u003c\/h3\u003e\r\nIndicated for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, in patients previously treated with at least 2 lines of systemic therapy\r\n\r\n60 mg PO on Days 1 and 3 of each week\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\n\u003ch4\u003eDosage reduction recommendations for adverse effects\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eSVd\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eStarting dose: 100 mg once weekly\u003c\/li\u003e\r\n \t\u003cli\u003eFirst reduction: 80 mg once weekly\u003c\/li\u003e\r\n \t\u003cli\u003eSecond reduction: 60 mg once weekly\u003c\/li\u003e\r\n \t\u003cli\u003eThird reduction: 40 mg once weekly\u003c\/li\u003e\r\n \t\u003cli\u003eFourth reduction: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eSd\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eStarting dose: 80 mg on Days 1 and 3 each week (160 mg\/week)\u003c\/li\u003e\r\n \t\u003cli\u003eFirst reduction: 100 mg once weekly\u003c\/li\u003e\r\n \t\u003cli\u003eSecond reduction: 80 mg once weekly\u003c\/li\u003e\r\n \t\u003cli\u003eThird reduction: 60 mg once weekly\u003c\/li\u003e\r\n \t\u003cli\u003eFourth reduction: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eDLBCL\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eStarting dose: 60 mg on Days 1 and 3 each week (120 mg\/week)\u003c\/li\u003e\r\n \t\u003cli\u003eFirst reduction: 40 mg Days 1 and 3 of each week (80 mg total per week)\u003c\/li\u003e\r\n \t\u003cli\u003eSecond reduction: 60 mg once weekly\u003c\/li\u003e\r\n \t\u003cli\u003eThird reduction: 40 mg once weekly\u003c\/li\u003e\r\n \t\u003cli\u003eFourth reduction: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797949542443,"sku":"RL1020230315900","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-06-194.jpg?v=1787022130"},{"product_id":"brukinsa-zanubrutinib","title":"BRUKINSA (Zanubrutinib)","description":"\u003cp\u003eBRUKINSA (Zanubrutinib) sold under the brand name 百悦泽 in china, is a BTK Inhibitor used to treat adults with:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eChronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL).\u003c\/li\u003e\n\u003cli\u003eWaldenström’s macroglobulinemia (WM).\u003c\/li\u003e\n\u003cli\u003eMantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.\u003c\/li\u003e\n\u003cli\u003eMarginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least one certain type of treatment.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eZanubrutinib was approved by FDA for medical use in the United States in November 2019.\u003c\/p\u003e\u003cp\u003eAs of November 17, 2023, Zanubrutinib was approved for medical use in 44 countries around the world.\u003c\/p\u003e","brand":"BeiGene Biotechnology, China","offers":[{"title":"Default Title","offer_id":44797952065579,"sku":"RL23202402","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-01-2228.png?v=1787022166"},{"product_id":"e6-9b-bf-e9-9b-b7-e5-88-a9-e7-8f-a0-e5-8d-95-e6-8a-97-ef-bc-88tislelizumab-ef-bc-89","title":"Tevimbra（Tislelizumab）","description":"Tevimbra (Tislelizumab-jsgr) sold under the brand name \u003cstrong\u003e百泽安\u003c\/strong\u003e in china, is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene’s immuno-oncology biologic program, and we believe it could serve as a key element of our immuno-oncology combination platform. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.\r\n\r\nThe FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) following prior systemic chemotherapy that did not include a PD-1\/PD-L1 inhibitor.","brand":"BeiGene Biotechnology, China","offers":[{"title":"Default Title","offer_id":44797952589867,"sku":"RL2320301801","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-03-1610.png?v=1787022181"},{"product_id":"generic-crizotinib-kesodx","title":"KESODX (Crizotinib)","description":"\u003ch2\u003eABout Crizotinib \u003c\/h2\u003e\u003cp\u003eCrizotinib is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1.\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Non-Small_Cell_Lung_Cancer\"\u003eNon-Small Cell Lung Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are anaplastic lymphoma kinase (ALK)- or ROS1-positive\u003c\/p\u003e\u003cp\u003e250 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Inflammatory_Myofibroblastic_tumors\"\u003eInflammatory Myofibroblastic tumors\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for unresectable, recurrent, or refractory inflammatory myofibroblastic tumors (IMT) in adults who are ALK-positive\u003c\/p\u003e\u003cp\u003e250 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 200 mg PO BID\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 250 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 250 mg PO qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797953081387,"sku":"RL3020241020","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-1235-jpg.webp?v=1787022192"},{"product_id":"tyvyt-sintilimab","title":"TYVYT  (Sintilimab)","description":"\u003cp\u003eTYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) is a fully human IgG4 monoclonal antibody, which specifically binds to PD-1 expressed on the surface of T cells to block the interaction between PD-L1 and PD-1, thereby reinvigorating exhausted T cell to gain effector function to kill tumor cells.\u003cbr\u003e\u003cbr\u003eIn December 2018, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was first approved by the China NMPA for the treatment of relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy.\u003c\/p\u003e\u003cp\u003eIn February 2021, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was approved by the China NMPA in combination with pemetrexed and platinum chemotherapy as first-line therapy for the treatment of nonsquamous non-small cell lung cancer.\u003c\/p\u003e\u003cp\u003eIn June 2021, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was approved by the China NMPA in combination with gemcitabine and platinum chemotherapy as the first-line therapy for the treatment of squamous non-small cell lung cancer.\u003c\/p\u003e\u003cp\u003eIn June 2021, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was approved by the China NMPA in combination with BYVASDA\u003csup\u003e®\u003c\/sup\u003e (bevacizumab biosimilar) as the first-line therapy for the treatment of Hepatocellular Carcinoma.\u003c\/p\u003e\u003cp\u003eIn December 2021, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was the only PD-1 inhibitor in China with four major indications (1L nsq NSCLC, 1L sq NSCLC, 1L HCC and cHL) approved and included in China’s NRDL.\u003c\/p\u003e\u003cp\u003eIn June 2022，TYVYT️\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was approved by the NMPA for the fifth indication in combination with cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).\u003cbr\u003e\u003cbr\u003eIn June 2022, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was approved by the NMPA for the sixth indication in combination with fluorouracil and platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.\u003c\/p\u003e","brand":"Innovent Bio, China","offers":[{"title":"Default Title","offer_id":44797954097195,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0711.jpg?v=1787022217"},{"product_id":"lcuipirto-pirtobrutinib","title":"LcuiPirto (Pirtobrutinib)","description":"\u003ch2\u003eAbout Pirtobrutinib \u003c\/h2\u003e\u003cp\u003ePirtobrutinib is an inhibits B cell lymphocyte proliferation and survival by binding and inhibiting Bruton's tyrosine kinase (BTK).\u003csup id=\"cite_ref-Aslan_2022_5-0\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch2\u003eMantle Cell Lymphoma\u003c\/h2\u003e\u003cp\u003eIndicated for relapsed or refractory mantle cell lymphoma (MCL) after at least 2 lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor\u003c\/p\u003e\u003cp\u003e200 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003eChronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma\u003c\/h2\u003e\u003cp\u003eIndicated for chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) in adults who have received at ≥2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor\u003c\/p\u003e\u003cp\u003e200 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003eDosage Modifications\u003c\/h2\u003e\u003cp\u003eAsymptomatic lymphocytosis: Dose modification not recommended\u003c\/p\u003e\u003cp\u003eAsymptomatic lipase increase: May not necessarily warrant a dose modification\u003c\/p\u003e\u003ch2\u003eHematologic toxicities\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eNOTE: Based on starting dose of 200 mg qDay\u003c\/li\u003e\n\u003cli\u003eAbsolute neutrophil count (ANC) 0.5 to \u0026lt;1 x 10\u003csup\u003e9\u003c\/sup\u003e\/L with fever and\/or infection\u003c\/li\u003e\n\u003cli\u003eANC \u0026lt;0.5 x 10\u003csup\u003e9\u003c\/sup\u003e\/L lasting ≥7 days\u003c\/li\u003e\n\u003cli\u003ePlatelet count 25 to \u0026lt;50 x 10\u003csup\u003e9\u003c\/sup\u003e\/L with bleeding\u003c\/li\u003e\n\u003cli\u003ePlatelet count \u0026lt;25 x 10\u003csup\u003e9\u003c\/sup\u003e\/L\u003c\/li\u003e\n\u003cli\u003e\n\u003ch3\u003eModification\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: Interrupt therapy until recovery to Grade 1 or baseline; restart at original dose (200 mg qDay)\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: Interrupt therapy until recovery to Grade 1 or baseline; restart at 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Interrupt therapy until recovery to Grade 1 or baseline; restart at 50 mg qDay\u003c\/li\u003e\n\u003cli\u003eFourth occurrence: Discontinue treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954162731,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0871.jpg?v=1787022218"},{"product_id":"anike-penpulimab","title":"Anike (Penpulimab)","description":"\u003ch2\u003eAbout \u003cspan data-huuid=\"5813577302449632437\"\u003ePenpulimab\u003c\/span\u003e\n\u003c\/h2\u003e\u003cp\u003e\u003cspan data-huuid=\"5813577302449632437\"\u003ePenpulimab is an IgG1 monoclonal antibody that's designed to eliminate Fcγ receptor binding and Fc-mediated effector functions. \u003c\/span\u003e\u003cspan data-huuid=\"5813577302449633568\"\u003eThis is intended to reduce immune-related adverse events (irAEs) while maintaining efficacy.\u003c\/span\u003e\u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003ePenpulimab \u003c\/span\u003e sold under the brand name 安尼可® (Anike) in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eIn August 2021, penpulimab received its first approval in China for the treatment of adult patients with relapsed or refractory classic Hodgkin's lymphoma who have undergone at least second-line chemotherapy. Penpulimab is under regulatory review for nasopharyngeal cancer and NSCLC in China. Clinical studies of penpulimab are underway for various cancers in China and Australia. This article summarizes the milestones in the development of penpulimab leading to this first approval for relapsed or refractory classic Hodgkin's lymphoma.\u003c\/p\u003e","brand":"Chia Tai Tianqing, China","offers":[{"title":"Default Title","offer_id":44797956325419,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-236.jpg?v=1787022257"},{"product_id":"zimberelimab","title":"Zimberelimab","description":"\u003cp\u003eZimberelimab  is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus Biosciences and Taiho Pharmaceutical Co. for the treatment of various cancers including cervical cancer, non-small cell lung cancer and classical Hodgkin's lymphoma. Based on the results of a phase II trial, zimberelimab was recently approved for marketing in China as treatment for relapsed or refractory classical Hodgkin's lymphoma. \u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eZimberelimab \u003c\/span\u003esold under the brand name 誉妥® in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eOn July 4, 2023, Zimberelimab was approved by NMPA for the treatment of recurrent or metastatic cervical cancer with positive PD-L1 expression (CPS ≥ 1) that has progressed after one or more lines of standard platinum-containing chemotherapy.\u003c\/p\u003e","brand":"Gloria Biosciences Co. Ltd., China","offers":[{"title":"Default Title","offer_id":44797956423723,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-2545.png?v=1787022260"},{"product_id":"epidaza-chidamide","title":"Epidaza (Chidamide)","description":"\u003cp\u003eChidamide (also named Tucidinostat) is a histone deacetylase (HDAC) inhibitor that is used to treat various cancers, including relapsed or refractory peripheral T cell lymphoma (PTCL) and pancreatic cancer:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eChidamide \u003c\/span\u003esold under the brand name 爱谱沙（Epidaza）® in china.\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eTucidinostat \u003c\/span\u003esold under the brand name Hiyasta ® in Japan.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eTucidinostat is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL) and has orphan drug status in Japan.\u003c\/p\u003e\u003cp\u003eIn Japan, it was approved for relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) treatment in June 2021.\u003csup id=\"cite_ref-4\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e","brand":"Chipscreen Bioscences,Ltd. China","offers":[{"title":"Default Title","offer_id":44797956456491,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-2793.jpg?v=1787022261"},{"product_id":"pitobrunib-pirtobrutinib","title":"Pitobrunib (Pirtobrutinib)","description":"\u003ch2\u003e\u003cspan id=\"About_Pirtobrutinib\"\u003eAbout Pirtobrutinib \u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003ePirtobrutinib is an inhibits B cell lymphocyte proliferation and survival by binding and inhibiting Bruton's tyrosine kinase (BTK).\u003csup id=\"cite_ref-Aslan_2022_5-0\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Mantle_Cell_Lymphoma\"\u003eMantle Cell Lymphoma\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eIndicated for relapsed or refractory mantle cell lymphoma (MCL) after at least 2 lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor\u003c\/p\u003e\u003cp\u003e200 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Chronic_Lymphocytic_LeukemiaSmall_Lymphocytic_Lymphoma\"\u003eChronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eIndicated for chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) in adults who have received at ≥2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor\u003c\/p\u003e\u003cp\u003e200 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eAsymptomatic lymphocytosis: Dose modification not recommended\u003c\/p\u003e\u003cp\u003eAsymptomatic lipase increase: May not necessarily warrant a dose modification\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Hematologic_toxicities\"\u003eHematologic toxicities\u003c\/span\u003e\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eNOTE: Based on starting dose of 200 mg qDay\u003c\/li\u003e\n\u003cli\u003eAbsolute neutrophil count (ANC) 0.5 to \u0026lt;1 x 10\u003csup\u003e9\u003c\/sup\u003e\/L with fever and\/or infection\u003c\/li\u003e\n\u003cli\u003eANC \u0026lt;0.5 x 10\u003csup\u003e9\u003c\/sup\u003e\/L lasting ≥7 days\u003c\/li\u003e\n\u003cli\u003ePlatelet count 25 to \u0026lt;50 x 10\u003csup\u003e9\u003c\/sup\u003e\/L with bleeding\u003c\/li\u003e\n\u003cli\u003ePlatelet count \u0026lt;25 x 10\u003csup\u003e9\u003c\/sup\u003e\/L\u003c\/li\u003e\n\u003cli\u003e\n\u003ch3\u003e\u003cspan id=\"Modification\"\u003eModification\u003c\/span\u003e\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: Interrupt therapy until recovery to Grade 1 or baseline; restart at original dose (200 mg qDay)\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: Interrupt therapy until recovery to Grade 1 or baseline; restart at 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Interrupt therapy until recovery to Grade 1 or baseline; restart at 50 mg qDay\u003c\/li\u003e\n\u003cli\u003eFourth occurrence: Discontinue treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797956522027,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-283.png?v=1787022262"},{"product_id":"golidocitinib","title":"Golidocitinib","description":"\u003cp\u003eGolidocitinib  \u003cspan class=\"xn-money\"\u003e(DZD4205) \u003c\/span\u003eis currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r\/r PTCL. In \u003cspan class=\"xn-chron\"\u003eJune 2024\u003c\/span\u003e, golidocitinib was approved by the National Medical Products Administration (NMPA) of \u003cspan class=\"xn-location\"\u003eChina\u003c\/span\u003e for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r\/r PTCL).\u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eGolidocitinib \u003c\/span\u003esold under the brand name 高瑞哲® in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003e《\u003ca href=\"https:\/\/www.prnewswire.com\/news-releases\/golidocitinib-approved-in-china-as-first-in-class-jak1-only-inhibitor-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma-302176781.html\"\u003eGolidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma\u003c\/a\u003e》\u003c\/p\u003e","brand":"Dizal Pharma, China","offers":[{"title":"Default Title","offer_id":44797956587563,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-3054.png?v=1787022264"},{"product_id":"anruixi-zuberitamab","title":"Anruixi (Zuberitamab)","description":"\u003cp\u003eZuberitamab is an innovative anti-CD20 monoclonal antibody injection. Zuberitamab is a biosimilar of rituximab, a monoclonal antibody which targets CD20.\u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eZuberitamab \u003c\/span\u003esold under the brand name 安瑞昔（Anruixi ）® in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eThis drug was approved by the Chinese National Medical Products Administration and was recently launched in diffuse large B lymphoma (\u003ca id=\"intref0020\" href=\"https:\/\/www.nmpa.gov.cn\/yaowen\/ypjgyw\/ypyw\/20230517152922112\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/www.nmpa.gov.cn\/yaowen\/ypjgyw\/ypyw\/20230517152922112\u003c\/a\u003e).\u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e","brand":"Bioray Biopharmaceutical Co. Ltd., China","offers":[{"title":"Default Title","offer_id":44797956620331,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-01-0266.jpg?v=1787022265"},{"product_id":"ripertamab","title":"Ripertamab","description":"\u003cp\u003eRipertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb.\u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eRipertamab \u003c\/span\u003esold under the brand name 安平希® in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eRipertamab  approval  from China’s NMPA to treat patients with CD20-positive diffuse large B-cell lymphoma. The country’s first homegrown anti-CD20 therapy, ripertamab has been shown to have similar efficacy to global blockbuster rituximab but with a superior safety profile.\u003c\/p\u003e","brand":"Sinocelltech Group Ltd, China","offers":[{"title":"Default Title","offer_id":44797956653099,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-01-033.jpg?v=1787022266"},{"product_id":"linperlisib","title":"Linperlisib","description":"\u003cp\u003eLinperlisib, a next-generation PI3Kδ-selective oral inhibitor, received marketing approval in China in 2022 for treatment of patients with relapsed and\/or refractory follicular lymphoma after two or more systemic therapies. Linperlisib also received U.S. FDA Orphan Drug Designations for follicular lymphoma, chronic lymphocytic leukemia, and T cell lymphomas. \u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eLinperlisib \u003c\/span\u003esold under the brand name 因他瑞® in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003e[Dosage and Administration]\u003c\/p\u003e\u003cp\u003eThe recommended dosage is 80 mg\/time (4 tablets, each containing 20 mg of \u003cspan data-huuid=\"5813577302449632437\"\u003eLinperlisib\u003c\/span\u003e), taken once a day, before or after meals, until disease progression or intolerable toxicity occurs.\u003c\/p\u003e\u003cp\u003ePrecautions During and after treatment with limplicel tablets, Pneumocystis jiroveci pneumonia (PJP) should be prevented until the absolute CD4+ T lymphocyte count is greater than 200 cells\/µL.\u003c\/p\u003e\u003cp\u003eFor any patient suspected of PJP, limplicel tablets should be suspended; patients diagnosed with PJP should stop taking limplicel tablets.\u003c\/p\u003e\u003cp\u003eDuring treatment with \u003cspan data-huuid=\"5813577302449632437\"\u003eLinperlisib \u003c\/span\u003e tablets, prophylactic use of antiviral drugs may be considered to prevent cytomegalovirus (CMV) infection and reactivation.\u003c\/p\u003e\u003cp\u003eDose adjustment Depending on the safety and tolerability of individual patients, it may be necessary to suspend the drug, reduce the dose, or permanently stop the drug.\u003c\/p\u003e","brand":"Yingli Pharmaceutical Co., Ltd., China","offers":[{"title":"Default Title","offer_id":44797956718635,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-01-0590.jpg?v=1787022267"},{"product_id":"innobruka-orelabrutinib","title":"INNOBRUKA (Orelabrutinib)","description":"\u003cp\u003eOrelabrutinib is a novel, highly selective, irreversible BTK inhibitor with high target selectivity and safety. \u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eOrelabrutinib \u003c\/span\u003esold under the brand name 宜诺凯（INNOBRUKA）® in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eIn China, it is approved for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL), who have received at least one treatment in the past.\u003csup id=\"cite_ref-1\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e","brand":"InnoCare Pharma, China","offers":[{"title":"Default Title","offer_id":44797956784171,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-01-0745.png?v=1787022269"},{"product_id":"lucidela-idelalisib","title":"LuciDela (Idelalisib)","description":"\u003ch2\u003eAbout Idelalisib\u003c\/h2\u003e\u003cp\u003eIdelalisib  is a medication used to treat certain blood cancers. Idelalisib acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase.\u003c\/p\u003e\u003ch3\u003eChronic Lymphocytic Leukemia\u003c\/h3\u003e\u003cp\u003eIndicated, in combination with rituximab, for relapsed chronic lymphocytic leukemia (CLL) in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities\u003c\/p\u003e\u003cp\u003eStarting dose: 150 mg PO BID; continue treatment until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eFollicular B-cell Non-Hodgkin Lymphoma\u003c\/h3\u003e\u003cp\u003eJanuary 14, 2022: Indication for relapsed follicular B-cell non-Hodgkin lymphoma withdrawn\u003c\/p\u003e\u003cp\u003eUnable to enroll enough patients into a confirmatory trial required for the accelerated approval\u003c\/p\u003e\u003ch3\u003eSmall Lymphocytic Lymphoma\u003c\/h3\u003e\u003cp\u003eJanuary 14, 2022: Indication for small lymphocytic lymphoma withdrawn\u003c\/p\u003e\u003cp\u003eUnable to enroll enough patients into a confirmatory trial required for the accelerated approval\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003ePneumonitis: Discontinue with any severity of symptomatic pneumonitis\u003c\/p\u003e\u003cp\u003eCrCl ≥15 mL\/min: No dose adjustment required\u003c\/p\u003e\u003ch4\u003eALT\/AST\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\u0026gt;3-5 x ULN: Maintain dose; monitor at least weekly until ≤1 x ULN\u003c\/li\u003e\n\u003cli\u003e\u0026gt;5-20 x ULN: Withhold idelalisib; monitor ALT\/AST at least weekly until ≤1 x ULN, then resume at 100 mg BID\u003c\/li\u003e\n\u003cli\u003e\u0026gt;20 x ULN: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eBilirubin\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\u0026gt;1.5-3 x ULN: Maintain dose; monitor at least weekly until≤1 x ULN\u003c\/li\u003e\n\u003cli\u003e\u0026gt;3-10 x ULN: Withhold idelalisib; monitor bilirubin at least weekly until ≤1 x ULN, then resume at 100 mg BID\u003c\/li\u003e\n\u003cli\u003e\u0026gt;10 x ULN: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eDiarrhea\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eModerate: Maintain dose; monitor at least weekly until resolved\u003c\/li\u003e\n\u003cli\u003eSevere or hospitalization: Withhold idelalisib; monitor at least weekly until resolved, then resume dose at 100 mg BID\u003c\/li\u003e\n\u003cli\u003eLife-threatening: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eNeutropenia\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eANC 1 to \u0026lt;1.5 Gi\/L: Maintain dose\u003c\/li\u003e\n\u003cli\u003eANC 0.5 to \u0026lt;1 Gi\/L: Maintain dose; monitor ANC at least weekly\u003c\/li\u003e\n\u003cli\u003eANC \u0026lt;0.5 Gi\/L: Withhold idelalisib; monitor ANC at least weekly until ANC ≥0.5 Gi\/L, then resume at 100 mg BID\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eThrombocytopenia\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003ePlatelets 50 to \u0026lt;75 Gi\/L: Maintain dose\u003c\/li\u003e\n\u003cli\u003ePlatelets 25 to \u0026lt;5 Gi\/L: Maintain dose; monitor platelets at least weekly\u003c\/li\u003e\n\u003cli\u003ePlatelets \u0026lt;25 Gi\/L: Withhold idelalisib; monitor platelets at least weekly until platelets ≥25 Gi\/L, then resume at 100 mg BID\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eInfections\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eEvidence of CMV infection or viremia\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt idelalisib in patients with evidence of active CMV infection of any grade or viremia (positive PCR or antigen test) until the viremia has resolved\u003c\/li\u003e\n\u003cli\u003eIf idelalisib is resumed, monitor patients by PCR or antigen test for CMV reactivation at least monthly\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade ≥3 sepsis or pneumonia\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eInterrupt idelalisib with until infection has resolved\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eEvidence of PJP infection\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt idelalisib in patients with suspected PJP infection of any grade\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue idelalisib if PJP infection is confirmed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eOther severe or life-threatening toxicities\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eWithhold drug until toxicity is resolved\u003c\/li\u003e\n\u003cli\u003eIf resuming treatment after interruption for other severe or life-threatening toxicities, reduce dose to 100 mg twice daily\u003c\/li\u003e\n\u003cli\u003eDiscontinue idelalisib permanently for recurrence of other severe or life-threatening idelalisib-related toxicity upon rechallenge\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eMonitoring\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eMonitor blood counts at least q2 weeks for first 6 months, and at least weekly if neutrophil counts \u0026lt;1x 10\u003csup\u003e9\u003c\/sup\u003e\/L\u003c\/li\u003e\n\u003cli\u003eMonitor ALT and AST q2 weeks for first 3 months, q4 weeks for next 3 months, then q1-3 months thereafter\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797957701675,"sku":"RL3520250416","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-04-1335.jpg?v=1787022291"}],"url":"https:\/\/xomeds.com\/collections\/lymphoma.oembed","provider":"XOMEDS","version":"1.0","type":"link"}